anti pde4b Search Results


pde4b antibody  (Bio-Techne corporation)
91
Bio-Techne corporation pde4b antibody
Pde4b Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pde4b antibody/product/Bio-Techne corporation
Average 91 stars, based on 1 article reviews
pde4b antibody - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier
anti-pde4b pd4-201ap  (FabGennix)
90
FabGennix anti-pde4b pd4-201ap
Anti Pde4b Pd4 201ap, supplied by FabGennix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pde4b pd4-201ap/product/FabGennix
Average 90 stars, based on 1 article reviews
anti-pde4b pd4-201ap - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-pde4b antibody  (Absolute Biotech Inc)
90
Absolute Biotech Inc anti-pde4b antibody
<t>PDE4B</t> expression regulates cAMP levels and PDE4B inhibition decreases Th2 differentiation and increases Th17 differentiation in DCs. (A , B) Expression profile of PDE mRNA expression in (A) WT DCs; n = 7 and (B) Δ Gnas DCs; n = 6. ND = not detected; data normalized to lowest-expressing detectable gene. (C) PDE4 isoform fold change in Δ Gnas DCs compared to WT cells; n = 5–6. (D) Western blots and (E) densitometry of Gα s and PDE4B protein expression in WT and Δ Gnas DCs; n = 4. (F) PDE activity in WT and Δ Gnas DCs; n = 5–6. (G) PDE4B expression after treatment of WT DCs with the adenylyl cyclase inhibitor MDL-12,330A (10μM, 16 h); n = 3. (H) PDE4B expression in WT and Δ Gnas DCs treated with a PKA inhibitor (PKI, 10 μM) for 24 h; n = 4. Data normalized to WT DMSO control. (I , J) Fold change in PDE4B expression after treatment of WT and Δ Gnas DCs with (I) PGE 2 (10μM, 24 h); n = 2-4, and (J) cAMP analogs CPT (non-selective, 50 μM, 24 h), 6MB (PKA-selective, 50 μM), and 8ME (Epac-selective, 50 μM) for 24 h; n = 3–5. Data normalized to WT vehicle control. (K,L) WT and Δ Gnas DCs were treated with DMSO (vehicle control), Ro 20-1724 (pan-PDE4 inhibitor, 10 μM), or A33 (PDE4B-selective inhibitor, 10 μM) for 24 h before culturing with CD4 + OT-II T cells. (K) IL-4 secretion and (L) IL-17 A secretion from co-cultured T cells was quantified; n = 4. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Anti Pde4b Antibody, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pde4b antibody/product/Absolute Biotech Inc
Average 90 stars, based on 1 article reviews
anti-pde4b antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-pde4b  (Abmart Inc)
90
Abmart Inc anti-pde4b
<t>PDE4B</t> expression regulates cAMP levels and PDE4B inhibition decreases Th2 differentiation and increases Th17 differentiation in DCs. (A , B) Expression profile of PDE mRNA expression in (A) WT DCs; n = 7 and (B) Δ Gnas DCs; n = 6. ND = not detected; data normalized to lowest-expressing detectable gene. (C) PDE4 isoform fold change in Δ Gnas DCs compared to WT cells; n = 5–6. (D) Western blots and (E) densitometry of Gα s and PDE4B protein expression in WT and Δ Gnas DCs; n = 4. (F) PDE activity in WT and Δ Gnas DCs; n = 5–6. (G) PDE4B expression after treatment of WT DCs with the adenylyl cyclase inhibitor MDL-12,330A (10μM, 16 h); n = 3. (H) PDE4B expression in WT and Δ Gnas DCs treated with a PKA inhibitor (PKI, 10 μM) for 24 h; n = 4. Data normalized to WT DMSO control. (I , J) Fold change in PDE4B expression after treatment of WT and Δ Gnas DCs with (I) PGE 2 (10μM, 24 h); n = 2-4, and (J) cAMP analogs CPT (non-selective, 50 μM, 24 h), 6MB (PKA-selective, 50 μM), and 8ME (Epac-selective, 50 μM) for 24 h; n = 3–5. Data normalized to WT vehicle control. (K,L) WT and Δ Gnas DCs were treated with DMSO (vehicle control), Ro 20-1724 (pan-PDE4 inhibitor, 10 μM), or A33 (PDE4B-selective inhibitor, 10 μM) for 24 h before culturing with CD4 + OT-II T cells. (K) IL-4 secretion and (L) IL-17 A secretion from co-cultured T cells was quantified; n = 4. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Anti Pde4b, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pde4b/product/Abmart Inc
Average 90 stars, based on 1 article reviews
anti-pde4b - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


PDE4B expression regulates cAMP levels and PDE4B inhibition decreases Th2 differentiation and increases Th17 differentiation in DCs. (A , B) Expression profile of PDE mRNA expression in (A) WT DCs; n = 7 and (B) Δ Gnas DCs; n = 6. ND = not detected; data normalized to lowest-expressing detectable gene. (C) PDE4 isoform fold change in Δ Gnas DCs compared to WT cells; n = 5–6. (D) Western blots and (E) densitometry of Gα s and PDE4B protein expression in WT and Δ Gnas DCs; n = 4. (F) PDE activity in WT and Δ Gnas DCs; n = 5–6. (G) PDE4B expression after treatment of WT DCs with the adenylyl cyclase inhibitor MDL-12,330A (10μM, 16 h); n = 3. (H) PDE4B expression in WT and Δ Gnas DCs treated with a PKA inhibitor (PKI, 10 μM) for 24 h; n = 4. Data normalized to WT DMSO control. (I , J) Fold change in PDE4B expression after treatment of WT and Δ Gnas DCs with (I) PGE 2 (10μM, 24 h); n = 2-4, and (J) cAMP analogs CPT (non-selective, 50 μM, 24 h), 6MB (PKA-selective, 50 μM), and 8ME (Epac-selective, 50 μM) for 24 h; n = 3–5. Data normalized to WT vehicle control. (K,L) WT and Δ Gnas DCs were treated with DMSO (vehicle control), Ro 20-1724 (pan-PDE4 inhibitor, 10 μM), or A33 (PDE4B-selective inhibitor, 10 μM) for 24 h before culturing with CD4 + OT-II T cells. (K) IL-4 secretion and (L) IL-17 A secretion from co-cultured T cells was quantified; n = 4. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: Frontiers in Pharmacology

Article Title: PDE4B Is a Homeostatic Regulator of Cyclic AMP in Dendritic Cells

doi: 10.3389/fphar.2022.833832

Figure Lengend Snippet: PDE4B expression regulates cAMP levels and PDE4B inhibition decreases Th2 differentiation and increases Th17 differentiation in DCs. (A , B) Expression profile of PDE mRNA expression in (A) WT DCs; n = 7 and (B) Δ Gnas DCs; n = 6. ND = not detected; data normalized to lowest-expressing detectable gene. (C) PDE4 isoform fold change in Δ Gnas DCs compared to WT cells; n = 5–6. (D) Western blots and (E) densitometry of Gα s and PDE4B protein expression in WT and Δ Gnas DCs; n = 4. (F) PDE activity in WT and Δ Gnas DCs; n = 5–6. (G) PDE4B expression after treatment of WT DCs with the adenylyl cyclase inhibitor MDL-12,330A (10μM, 16 h); n = 3. (H) PDE4B expression in WT and Δ Gnas DCs treated with a PKA inhibitor (PKI, 10 μM) for 24 h; n = 4. Data normalized to WT DMSO control. (I , J) Fold change in PDE4B expression after treatment of WT and Δ Gnas DCs with (I) PGE 2 (10μM, 24 h); n = 2-4, and (J) cAMP analogs CPT (non-selective, 50 μM, 24 h), 6MB (PKA-selective, 50 μM), and 8ME (Epac-selective, 50 μM) for 24 h; n = 3–5. Data normalized to WT vehicle control. (K,L) WT and Δ Gnas DCs were treated with DMSO (vehicle control), Ro 20-1724 (pan-PDE4 inhibitor, 10 μM), or A33 (PDE4B-selective inhibitor, 10 μM) for 24 h before culturing with CD4 + OT-II T cells. (K) IL-4 secretion and (L) IL-17 A secretion from co-cultured T cells was quantified; n = 4. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Afterwards, they were stripped (ThermoFisher Scientific, 21,059) per manufacturer’s instructions, washed, blocked with 5% milk/1X TBST, and re-incubated with mouse anti-PDE4B antibody (LSBio, LS-B11018; 1:500 dilution) in 2.5% milk/TBST at 4°C overnight on a shaker.

Techniques: Expressing, Inhibition, Western Blot, Activity Assay, Cell Culture